Global Subunit And Conjugate Veterinary Vaccines Market
Market Size in USD Billion
CAGR :
%

![]() |
2025 –2032 |
![]() |
USD 686.30 Million |
![]() |
USD 1,020.95 Million |
![]() |
|
![]() |
Global Subunit and Conjugate Veterinary Vaccines Market Segmentation, By Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Companion Animal Vaccines, Aquaculture Vaccines and, Other Animal Vaccines), Disease (Porcine, Poultry, Livestock, Companion Animals, and Aquaculture), Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Other Vaccines), Route of Administration (Oral, Parenteral, and Topical), End-Use (Hospitals and Clinics) – Industry Trends and Forecast to 2032
Subunit and Conjugate Veterinary Vaccines Market Analysis
The Subunit and Conjugate Veterinary Vaccines Market has been growing due to the increasing demand for more effective and safer vaccines for both companion animals and livestock. Subunit vaccines, being more specific and targeted, reduce the risk of side effects compared to traditional vaccines, which is a key factor driving their adoption. In addition, the rise of zoonotic diseases and the need for advanced vaccine solutions that provide better protection with fewer adverse reactions have increased the focus on subunit and conjugate vaccine development.
The demand for conjugate vaccines, which enhance immune responses by linking antigens to carrier proteins, is particularly notable in livestock, where they help prevent bacterial infections. The growing awareness of animal health and the importance of vaccination in disease prevention has contributed to the expansion of this market.
The market is also fueled by advancements in biotechnology and vaccine formulation, allowing for the development of more efficient and cost-effective products. Veterinary professionals are increasingly adopting these vaccines due to their precision, which helps in managing diseases such as rabies, parvovirus, and bacterial infections. With rising awareness, strict regulations, and a shift towards more specialized vaccines, the Subunit and Conjugate Veterinary Vaccines Market is expected to continue its growth trajectory.
Subunit and Conjugate Veterinary Vaccines Market Size
The global subunit and conjugate veterinary vaccines market size was valued at USD 686.3 million in 2024 and is projected to reach USD 1,020.95 million by 2032, with a CAGR of 5.09% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Subunit and Conjugate Veterinary Vaccines Market Trends
“Increasing Demand for Safer and More Precise Immunization Solutions.”
Subunit and Conjugate Veterinary Vaccines are trending because of the increasing demand for safer and more precise immunization solutions. Unlike traditional vaccines that often use whole pathogens, subunit and conjugate vaccines target specific components (such as proteins or sugars) of the pathogen, reducing the risk of adverse reactions in animals. This makes them ideal for both companion animals and livestock, where safety is critical. In addition, these vaccines offer enhanced efficacy by boosting the immune response, especially in cases where animals have weakened immune systems or are at high risk for infections. As zoonotic diseases, such as rabies and parvovirus, continue to pose threats, and as awareness of animal health grows, there is a rising preference for vaccines that provide targeted, effective protection with fewer side effects. This growing shift toward safer, more specialized vaccines is a major driver of the market's expansion.
Report Scope and Subunit and Conjugate Veterinary Vaccines Market Segmentation
Attributes |
Subunit and Conjugate Veterinary Vaccines Key Market Insights |
Segments Covered |
|
Countries Covered |
U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America |
Key Market Players |
ARKO Laboratories (U.K.), AquaBounty Technologies, Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Biogénesis Bagó S.A. (Argentina), Ceva (France), Dechra Pharmaceuticals Limited (U.K.), Elanco (U.S.), FeedVax, Inc. (Argentina), HIPRA, S.A. (Spain), HESTER BIOSCIENCES LIMITED (India), Intervacc AB (Sweden), IDEXX (U.S.), Indian Immunologicals Ltd. (India), LABORATORIO AVI-MEX, SA DE CV (Mexico), Merck & Co., Inc. (U.S.), Neogen Corporation (U.S.), Phibro Animal Health Corporation (U.S.), Virbac (France), Vetoquinol (France) and Zoetis Services LLC (U.S.) |
Market Opportunities |
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Subunit and Conjugate Veterinary Vaccines Market Definition
Subunit Veterinary Vaccines are vaccines that contain only specific parts of the pathogen, such as proteins, sugars, or other molecules that trigger an immune response without using the entire pathogen. These vaccines do not contain live or whole pathogens, which reduces the risk of adverse reactions while still providing effective immunity.
Conjugate Veterinary Vaccines are a type of vaccine where an antigen (often a polysaccharide from a pathogen) is chemically linked (or "conjugated") to a carrier protein. This helps enhance the immune response, especially in animals with underdeveloped or weakened immune systems, such as young animals. By improving the immune system's recognition and response, conjugate vaccines provide better protection against certain bacterial infections that might otherwise be difficult to target.
Subunit and Conjugate Veterinary Vaccines Market Dynamics
Drivers
- Increasing Focus on Animal Health and Disease Prevention
As awareness of animal health and welfare continues to rise, there is a growing emphasis on preventing infectious diseases through vaccination. Zoonotic diseases, which can be transmitted from animals to humans, such as rabies and avian influenza, have further spurred the demand for safer, more effective vaccines. Subunit and conjugate vaccines are especially attractive because they offer targeted immunity with fewer side effects compared to traditional vaccines. For instance, the use of conjugate vaccines for bacterial infections in livestock, such as Haemophilus somnus in cattle, demonstrates their growing application. These vaccines provide better protection against pathogens without the risk of adverse reactions associated with whole-pathogen vaccines. The increased focus on disease prevention and animal welfare is driving the adoption of subunit and conjugate vaccines, boosting market demand and growth.
- Advancements in Biotechnology and Vaccine Development
Technological advancements in biotechnology have enabled the creation of more effective and specific vaccines. Subunit and conjugate vaccines, made possible by these advancements, offer precise targeting of pathogens while minimizing risk. For instance, recombinant DNA technology is used to produce subunit vaccines, such as those for parvovirus in dogs, which provide immunity with high specificity. Similarly, conjugate vaccines, such as those for Streptococcus pneumoniae in poultry, offer enhanced protection against bacterial diseases. These vaccines are especially beneficial for young animals whose immune systems are not fully developed. These ongoing advancements in biotechnology are enhancing the development of these specialized vaccines, driving innovation and increasing their adoption in veterinary medicine, thus accelerating market growth.
Opportunities
- Expansion in Emerging Markets
Emerging markets, especially in Asia-Pacific and Latin America, present significant opportunities for the growth of subunit and conjugate veterinary vaccines. As economies in these regions develop, there is an increasing focus on improving livestock health and productivity to meet rising food demands. For instance, in countries such as India and China, the growing poultry and cattle industries are adopting more advanced vaccination methods to prevent diseases such as avian influenza and foot-and-mouth disease. Conjugate vaccines, which offer better protection against bacterial infections, and subunit vaccines for viral diseases are becoming more widely used. The expansion of animal agriculture in these emerging markets provides a major opportunity for the introduction of safer, more effective veterinary vaccines, driving demand and fueling market growth.
- Growing Investment in Veterinary Vaccine R&D
The veterinary vaccine sector is benefiting from increased investment in research and development (R&D). As global concerns about antibiotic resistance and the rise of new diseases grow, there is a push for alternatives, such as vaccines, to prevent infections in animals. For instance, the development of subunit vaccines for rabies and the creation of conjugate vaccines for bovine respiratory diseases are key areas of innovation. Many pharmaceutical companies are increasing their R&D budgets to improve vaccine efficacy, reduce costs, and address unmet needs in veterinary care. Increased R&D investment is driving the development of more targeted, effective vaccines, enhancing market offerings and expanding the adoption of subunit and conjugate vaccines in veterinary medicine.
Restraints/Challenges
- High Production Costs
One major restraint in the growth of the Subunit and Conjugate Veterinary Vaccines Market is the high production cost associated with these vaccines. Manufacturing these vaccines requires advanced biotechnology techniques, including recombinant DNA technology, protein purification, and conjugation processes. For instance, the production of recombinant protein-based subunit vaccines such as those for feline leukemia or canine parvovirus is costly due to the complexity of the procedures involved. In addition, conjugate vaccines, which often require specialized carrier proteins, can increase costs further. These high production costs can make vaccines more expensive for farmers and pet owners, limiting their adoption in price-sensitive markets. These high costs pose a challenge to market growth.
- Regulatory Approval and Safety Concerns
A significant challenge for subunit and conjugate veterinary vaccines is navigating the regulatory approval process and addressing safety concerns. Regulatory bodies, such as the U.S. FDA or European Medicines Agency, require rigorous testing and data to demonstrate the safety and efficacy of new vaccines. The process can be time-consuming and expensive, especially for new vaccine types that have not been widely used. For instance, novel conjugate vaccines for diseases such as Brucella in livestock or Leptospira in dogs may face lengthy approval processes, delaying their market entry. In addition, some animal owners may have concerns about the long-term effects of newer vaccines, further challenging their adoption. These regulatory hurdles slow the speed of market entry.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Subunit and Conjugate Veterinary Vaccines Market Scope
The market is segmented on the basis of type, disease, technology, route of administration, and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Porcine Vaccines
- Poultry Vaccines
- Livestock Vaccines
- Companion Animal Vaccines
- Aquaculture Vaccines
- Other Animal Vaccines
Disease
- Porcine
- Poultry
- Livestock
- Companion Animals
- Aquaculture
Technology
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Other Vaccines
Route of Administration
- Oral
- Parenteral
- Topical
End-Use
- Hospitals
- Clinics
Subunit and Conjugate Veterinary Vaccines Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, disease, technology, route of administration, and end-use as referenced above.
The countries covered in the market report are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
North America is expected to dominate the Subunit and Conjugate Veterinary Vaccines Market due to the region’s well-established healthcare infrastructure, advanced veterinary practices, and high investment in animal health. The United States, in particular, plays a key role, with a large number of major pharmaceutical and vaccine manufacturers, along with a strong regulatory framework that supports the development and distribution of veterinary vaccines.
Asia Pacific (APAC) region is expected to exhibit the highest growth rate in the Subunit and Conjugate Veterinary Vaccines Market, driven by factors such as rapid economic development, increasing livestock populations, and a growing demand for animal products. Countries such as China, India, and Southeast Asian nations are seeing significant advancements in veterinary healthcare, with rising awareness about animal diseases and the importance of vaccination. In addition, the expansion of pet ownership and the increasing recognition of zoonotic diseases are further fueling demand for veterinary vaccines.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Subunit and Conjugate Veterinary Vaccines Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Subunit and Conjugate Veterinary Vaccines Market Leaders Operating in the Market Are
- ARKO Laboratories (U.K.)
- AquaBounty Technologies, Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Biogénesis Bagó S.A. (Argentina)
- Ceva (France)
- Dechra Pharmaceuticals Limited (U.K.)
- Elanco (U.S.)
- FeedVax, Inc. (Argentina)
- HIPRA, S.A. (Spain)
- HESTER BIOSCIENCES LIMITED (India)
- Intervacc AB (Sweden)
- IDEXX (U.S.)
- Indian Immunologicals Ltd. (India)
- LABORATORIO AVI-MEX, SA DE CV (Mexico)
- Merck & Co., Inc. (U.S.)
- Neogen Corporation (U.S.)
- Phibro Animal Health Corporation (U.S.)
- Virbac (France)
- Vetoquinol (France)
- Zoetis Services LLC (U.S.)
Latest Developments in Subunit and Conjugate Veterinary Vaccines Market
- In January 2025, Intervacc AB (publ) received orders from Dechra Pharmaceuticals totaling approximately SEK 5.8 million. These orders are for Strangvac, a vaccine designed to protect horses from the highly contagious and severe infectious disease, strangles. The order covers vaccine vials for the UK, Germany, France, the Netherlands, Belgium, and Austria, with delivery expected within the next 3 to 4 months.
- In November 2024, Boehringer Ingelheim announced the launch of its latest advanced Marek’s disease vaccine in India. This next-generation vaccine provides enhanced protection through an innovative controlled attenuation process, ensuring an optimal balance between safety and efficacy. Marek’s disease continues to be a major challenge in Indian poultry, with outbreaks persisting despite widespread vaccination. This new vaccine addresses this issue with a groundbreaking serotype-1 construct, offering effective protection against the most virulent strains while maintaining safety.
- In September 2024, Elanco Animal Health Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved Zenrelia, a safe, highly effective, and convenient once-daily oral JAK inhibitor for managing pruritus (itching) associated with allergic dermatitis and controlling atopic dermatitis in dogs aged 12 months and older. The approval of Zenrelia marks a significant advancement in treating dogs with chronic, acute, or seasonal itching and inflammation, offering relief through a single, once-daily tablet from the start.
- In August 2024, Intervacc AB (publ) and the Karolinska Institute (KI) announced the extension of their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension ensures that the research team at the Karolinska Institutet, led by Professor Birgitta Henriques Normark, will continue to be an integral part of the successful partnership between KI, the Swedish University of Agricultural Sciences (SLU), and Intervacc.
- In October 2023, the University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization (VIDO) signed a memorandum of understanding (MOU) with the Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM) at The Pirbright Institute. This MOU paves the way for expanded collaborations and training in vaccine manufacturing, aiming to drive innovations in animal health.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.